• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Intrathecal tofersen can reduce superoxide dismutase concentration in cerebrospinal fluid of ALS patients

byHarsh ShahandDeepti Shroff Karhade
July 8, 2020
in Chronic Disease, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. A 100mg treatment of tofersen was shown to decrease cerebrospinal fluid (CSF) superoxide dismutase 1 (SOD1) concentration in adults with amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.

2. Lumbar puncture-related adverse events were shown to be present in most participants.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Amyotrophic lateral sclerosis, resulting from superoxide dismutase 1 (SOD1) mutations consist of approximately 2% of all cases with over 180 disease-causing mutations identified within the gene. Tofersen is an antisense oligonucleotide (ASO) which mediates SOD1 mRNA degradation, thereby, reducing the synthesis of SOD1 protein. However, the effect of tofersen dosing on patients diagnosed with ALS is unknown. As such, this study evaluated the safety, pharmacokinetics, and pharmacodynamics of tofersen in adults with SOD1 mutation mediated ALS. Intrathecal administration of tofersen was shown to significant reduce CSF SOD1 concentrations. While, this study was adequately powered to test the reduction of SOD1 concentration in the CSF, the study was not able to conclusively determine other clinical or biological measures due to its low power. Nonetheless, this study was strengthened by its extensive follow-up period and the additional analyses conducted on the exploratory nature of the efficacy outcomes.

Click to read the study, published today in NEJM

Relevant reading: Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models

In-Depth [randomized controlled trial]: This randomized control trial enrolled 50 patients across 18 sites in the United States, Canada, and Western Europe. Patients enrolled in the study were adults over the age of 18 years with muscle weakness attributed to ALS, documented SOD1 mutation, and normal coagulation variables. The exclusion criteria for the study included participants currently taking or scheduled to start edaravone treatment. Patients were randomized in a 3:1 ratio to receive 20, 40, 60, or 100 mg tofersen doses or a placebo regimen. A single dose of the treatment was administered on days 1, 15, 29, 57, and 85. The primary outcome was treatment safety. The most common adverse events included headache (16 participants, 32%), procedural pain (16 participants, 32%), and post-lumbar puncture syndrome (13 participants, 26%). The difference in ratio of CSF SOD1 concentration between baseline and day 85 for the 20-mg group was 2 percentage points (95% confidence interval [CI], -18 to 27) compared to the placebo group. The difference in ratio of CSF SOD1 concentration for the 40-mg group was -25 percentage points (95% CI, -40 to -5) compared to the placebo group. The difference in ratio of CSF SOD1 concentration for the 60-mg group was -19 percentage points (95% CI, -35 to 2) compared to the placebo group. The difference in ratio of CSF SOD1 concentration for the 100-mg group was -33 percentage points (95% CI, -47 to -16) compared to the placebo group. Taken together, the 100-mg tofersen treatment was shown to decrease SOD1 concentration in adults with ALS with associated procedural-related adverse events.

RELATED REPORTS

CT not sufficient to rule out early subarachnoid hemorrhage [Classics Series]

Lumbar puncture rates appropriately decline in children with simple febrile seizures

Variants in the SPTLC1 gene associated with juvenile amyotrophic lateral sclerosis

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: amyotrophic lateral sclerosis (ALS)cerebrospinal fluidlumbar puncturesuperoxide dismutase 1 (SOD1)
Previous Post

Adolescent behaviours toward COVID-19 driven by perception of disease severity

Next Post

Autopsy rates significantly higher among Black persons in the US

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Neurology Classics

CT not sufficient to rule out early subarachnoid hemorrhage [Classics Series]

September 7, 2022
Social networks play key roles in parental vaccination decisions
Infectious Disease

Lumbar puncture rates appropriately decline in children with simple febrile seizures

October 21, 2021
Quick Take: Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography
Chronic Disease

Variants in the SPTLC1 gene associated with juvenile amyotrophic lateral sclerosis

September 3, 2021
Quick Take: Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography
Neurology

Ezogabine with potential to slow disease progression for amyotrophic lateral sclerosis in phase 2 trial

December 1, 2020
Next Post
Autopsy rates significantly higher among Black persons in the US

Autopsy rates significantly higher among Black persons in the US

Autopsy rates significantly higher among Black persons in the US

Nurse-administered interventions in the community may not reduce the rate of first fall injury

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options